20/20 Biolabs Inc (NASDAQ:AIDX – Get Free Report) was the recipient of a large increase in short interest in the month of October. As of October 30th, there was short interest totaling 57,001 shares, an increase of 405.8% from the October 15th total of 11,270 shares. Approximately 0.6% of the shares of the company are sold short. Based on an average daily volume of 160,271 shares, the short-interest ratio is presently 0.4 days.
20/20 Biolabs Stock Performance
AIDX stock opened at $0.20 on Wednesday. The stock has a market capitalization of $2.61 million and a P/E ratio of -0.36. The company has a 50 day moving average price of $0.37 and a two-hundred day moving average price of $0.96. 20/20 Biolabs has a one year low of $0.18 and a one year high of $50.00.
20/20 Biolabs (NASDAQ:AIDX – Get Free Report) last released its earnings results on Friday, August 14th. The company reported ($0.26) earnings per share for the quarter. The company had revenue of $0.73 million during the quarter.
Wall Street Analysts Forecast Growth
Separately, Weiss Ratings reiterated a “sell (e)” rating on shares of 20/20 Biolabs in a report on Friday, October 30th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $5.00.
Read Our Latest Research Report on 20/20 Biolabs
20/20 Biolabs Company Profile
We develop and commercialize AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. We offer two families of lab tests, both under our OneTest brand: (i) OneTest for Cancer, a multi-cancer early detection, or MCED, blood test which has been our primary commercial focus and source of revenues since we wound down our COVID-19 testing business, and (ii) OneTest for Longevity, which measures inflammatory biomarkers, that we expect to launch in the first half of 2026.
See Also
- Five stocks we like better than 20/20 Biolabs
- The AI Debt Bill Is Coming Due, But Biotech Has Revenue to Show for the Boom
- 3 Insider Selling Stories; 3 Different Signals for Investors
- The Trade Desk Beats on Revenue, But the Fine Print Matters
- Poll Reveals: Which States Are Most Prepared for a Crisis? [2026]
Receive News & Ratings for 20/20 Biolabs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 20/20 Biolabs and related companies with MarketBeat.com's FREE daily email newsletter.
